Skip to main content Accessibility help
  • Print publication year: 2019
  • Online publication date: April 2019

19 - Pharmacologic-Augmented Treatments

from Part II - Obsessive-Compulsive Disorder

Related content

Powered by UNSILO
Andersson, E., Hedman, E., Enander, J. M., Radu Djurfeldt, D., Ljotsson, B., Cervenka, S.,… Ruck, C. (2015). D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 72(7), 659667. doi:10.1001/jamapsychiatry.2015.0546
Bloch, M. H., & Storch, E. A. (2015). Assessment and management of treatment-refractory obsessive-compulsive disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry, 54(4), 251262. doi:10.1016/j.jaac.2015.01.011
Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017). D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PloS One, 12(3), e0173660. doi:10.1371/journal.pone.0173660
Bussing, R., Reid, A. M., McNamara, J. P. H., Meyer, J. M., Guzick, A. G., Mason, D. M.,… Murphy, T. K. (2015). A pilot study of actigraphy as an objective measure of SSRI activation symptoms: Results from a randomized placebo controlled psychopharmacological treatment study. Psychiatry Research, 225(3), 440445. doi:10.1016/j.psychres.2014.11.070
Caporino, N. E., & Storch, E. A. (2016). Personalizing the treatment of pediatric obsessive-compulsive disorder: Evidence for predictors and moderators of treatment outcomes. Current Behavioral Neuroscience Reports, 3(1), 7385. doi:10.1007/s40473-016–0066-5
Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T.,… Wilhelm, S. (2010). Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy, 48(7), 675679. doi:10.1016/j.brat.2010.03.007
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006). Effects of D-Cycloserine on extinction: Translation from preclinical to clinical work. Biological Psychiatry, 60(4), 369375. doi:10.1016/j.biopsych.2006.03.084
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 16(3), 557574. doi:10.1017/s1461145712000740
Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L.,… Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depression and Anxiety, 30(8), 723731. doi:10.1002/da.22132
Franklin, M. E., Kratz, H. E., Freeman, J. B., Ivarsson, T., Heyman, I., Sookman, D.,… March, J. (2015). Cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: Empirical review and clinical recommendations. Psychiatry Research, 227(1), 7892. doi:10.1016/j.psychres.2015.02.009
Franklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D.,… March, J. S. (2011). Cognitive-behavior therapy augmentation of pharmacotherapy in pediatric obsessive compulsive disorder: The pediatric OCD treatment study II (POTS II) randomized, controlled trial. JAMA, 306(11), 12241232. doi:10.1001/jama.2011.1344
Garcia, A. M., Sapyta, J. J., Moore, P. S., Freeman, J. B., Franklin, M. E., March, J. S., & Foa, E. B. (2010). Predictors and moderators of treatment outcome in the pediatric obsessive compulsive treatment study (POTS I). Journal of the American Academy of Child and Adolescent Psychiatry, 49(10), 10241033. doi:10.1016/j.jaac.2010.06.013
Geller, D. A., March, J., & AACAP Committee on Quality Issues. (2012). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 98113. doi:10.1016/j.jaac.2011.09.019
Goodman, W. K., Murphy, T. K., & Storch, E. A. (2007). Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology, 191(1), 8796. doi:10.1007/s00213-006–0642-6
Grabb, M. C., & Gobburu, J. V. S. (2017). Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology. Progress in Neurobiology, 152, 3857. doi:10.1016/j.pneurobio.2016.05.003
Graham, B. M., Callaghan, B. L., & Richardson, R. (2014). Bridging the gap: Lessons we have learnt from the merging of psychology and psychiatry for the optimisation of treatments for emotional disorders. Behaviour Research and Therapy, 62, 316. doi:10.1016/j.brat.2014.07.012
Gu, W., Storch, E. A., Zhao, Q., Xu, T., & Wang, Z. (2017). Effects of D-cycloserine augmentation on cognitive behavioral therapy in patients with obsessive-compulsive disorder: A systematic review and meta-analysis. Journal of Obsessive-Compulsive and Related Disorders, 13, 2429. doi:10.1016/j.jocrd.2017.03.001
Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332339. doi:10.1001/archpsyc.63.3.332
Hilt, R. J., Chaudhari, M., Bell, J. F., Wolf, C., Koprowicz, K., & King, B. H. (2014). Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 24(2), 8389. doi:10.1089/cap.2013.0036
Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. (2015). d-Cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: An update. Current Psychiatry Reports, 17(1), 532. doi:10.1007/s11920-014–0532-2
Ivarsson, T., Skarphedinsson, G., Kornør, H., Axelsdottir, B., Biedilæ, S., Heyman, I.,… March, J. (2015). The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis. Psychiatry Research, 227(1), 93103. doi:10.1016/j.psychres.2015.01.015
Kim, J. H., & Richardson, R. (2010). New findings on extinction of conditioned fear early in development: Theoretical and clinical implications. Biological Psychiatry, 67(4), 297303. doi:10.1016/j.biopsych.2009.09.003
Lewin, A. B., McGuire, J. F., Murphy, T. K., & Storch, E. A. (2014). Editorial perspective: The importance of considering parent’s preferences when planning treatment for their children – the case of childhood obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry, 55(12), 13141316. doi:10.1111/jcpp.12344
Lewin, A. B., Peris, T. S., Lindsey Bergman, R., McCracken, J. T., & Piacentini, J. (2011). The role of treatment expectancy in youth receiving exposure-based CBT for obsessive compulsive disorder. Behaviour Research and Therapy, 49(9), 536543. doi:10.1016/j.brat.2011.06.001
Lewin, A. B., Piacentini, J., De Nadai, A. S., Jones, A. M., Peris, T. S., Geffken, G. R., … Storch, E. A. (2014). Defining clinical severity in pediatric obsessive-compulsive disorder. Psychological Assessment, 26(2), 679684. doi:10.1037/a0035174
March, J. S., Franklin, M. E., Leonard, H., Garcia, A., Moore, P., Freeman, J., & Foa, E. (2007). Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry, 61(3), 344347. doi:10.1016/j.biopsych.2006.09.035
Maron, E., & Nutt, D. (2015). Biological predictors of pharmacological therapy in anxiety disorders. Dialogues in Clinical Neuroscience, 17(3), 305317.
Masi, G., Pfanner, C., Millepiedi, S., & Berloffa, S. (2010). Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 30(6), 688693. doi:10.1097/JCP.0b013e3181fab7b1
Mataix-Cols, D., de la Cruz, Fernandez, Monzani, L., Rosenfield, B., Andersson, D., Pérez-Vigil, E., A.,… the DCS Anxiety Consortium. (2017). D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry, 74(5), 501510. doi:10.1001/jamapsychiatry.2016.3955
Mataix-Cols, D., Turner, C. M., Monzani, B., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2014). Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry, 204(1), 7778. doi:10.1192/bjp.bp.113.126284
McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014). Enhancing exposure therapy for anxiety disorders, obsessive compulsive disorder, and posttraumatic stress disorder. Expert Review of Neurotherapeutics, 14(8), 893910. doi:10.1586/14737175.2014.934677
McGuire, J. F., Piacentini, J., Lewin, A. B., Brennan, E. A., Murphy, T. K., & Storch, E. A. (2015). A meta-analysis of cognitive behavior therapy and medication for child obsessive–compulsive disorder: Moderators of treatment efficacy, response, and remission. Depression and Anxiety, 32(8), 580593. doi:10.1002/da.22389
Neziroglu, F., Yaryura-Tobias, J. A., Walz, J., & McKay, D. (2000). The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 10(4), 295306. doi:10.1089/cap.2000.10.295
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry, 63(12), 11181126. doi:10.1016/j.biopsych.2008.01.012
O’Neill, J., Piacentini, J., Chang, S., Ly, R., Lai, T. M., Armstrong, C. C., … Nurmi, E. L. (2017). Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: Randomized clinical trial. Neuropsychopharmacology, 42, 24142422. doi:10.1038/npp.2017.77
Ori, R., Amos, T., Bergman, H., Soares-Weiser, K., Ipser, J. C., & Stein, D. J. (2015). Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database of Systematic Reviews (5), Cd007803. doi:10.1002/14651858.CD007803.pub2
Öst, L.-G., Riise, E. N., Wergeland, G. J., Hansen, B., & Kvale, G. (2016). Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis. Journal of Anxiety Disorders, 43, 5869. doi:10.1016/j.janxdis.2016.08.003
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A.,… Pollack, M. H. (2016). Enhancement of psychosocial treatment with d-cycloserine: Models, moderators, and future directions. Biological Psychiatry, 80(4), 274283. doi:10.1016/j.biopsych.2015.09.007
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010). Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes. [Clinical psychology : a publication of the Division of Clinical Psychology of the American Psychological Association]. Clinical Psychology, 17(2), 91103. doi:10.1111/j.1468–2850.2010.01198.x
Pittenger, C. (2015a). Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatric Annals, 45(6), 308315. doi:10.3928/00485713–20150602-06
Pittenger, C. (2015b). Glutamatergic agents for OCD and related disorders. Current Treatment Options in Psychiatry, 2(3), 271283. doi:10.1007/s40501-015–0051-8
Pontoski, K. E., & Heimberg, R. G. (2010). The myth of the superiority of concurrent combined treatments for anxiety disorders. Clinical Psychology: Science and Practice, 17(2), 107111. doi:10.1111/j.1468–2850.2010.01200.x
Rapee, R. M., Jones, M. P., Hudson, J. L., Mahli, G. S., Lyneham, H. J., & Schneider, S. C. (2016). d-Cycloserine does not enhance the effects of in-vivo exposure among young people with broad-based anxiety disorders. Behaviour Research and Therapy, 87, 225231. doi:10.1016/j.brat.2016.10.004
Reid, A. M., McNamara, J. P. H., Murphy, T. K., Guzick, A. G., Storch, E. A., Geffken, G. R., & Bussing, R. (2015). Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. Journal of Psychiatric Research, 71, 140147. doi:10.1016/j.jpsychires.2015.10.006
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016). Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. Neuroscience and Biobehavioral Reviews, 60, 5164. doi:10.1016/j.neubiorev.2015.11.008
Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K.,… Leckman, J. F. (1997). Children’s Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844852. doi:10.1097/00004583–199706000-00023
Simpson, H., Foa, E. B., Liebowitz, M. R., & et al. (2013). Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 70(11), 11901199. doi:10.1001/jamapsychiatry.2013.1932
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology and Therapeutics, 149, 150190. doi:10.1016/j.pharmthera.2014.12.004
Skarphedinsson, G., Weidle, B., Thomsen, P. H., Dahl, K., Torp, N. C., Nissen, J. B.,… Ivarsson, T. (2015). Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive–compulsive disorder that were non-responders to cognitive-behavior therapy: A randomized controlled trial. European Child and Adolescent Psychiatry, 24(5), 591602. doi:10.1007/s00787-014–0613-0
Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J.,… Tart, C. D. (2013). D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biological Psychiatry, 73(11), 10541058. doi:10.1016/j.biopsych.2012.12.009
Stewart, S. E., & Stachon, A. C. (2014). Pharmacotherapy for obsessive-compulsive and related disorders among children and adolescents. In Storch, E. A. & McKay, D. E. (eds.), Obsessive-compulsive disorder and its spectrum: A life-span approach (pp. 293316). Washington, DC: American Psychological Association.
Storch, E. A., Bussing, R., Small, B. J., Geffken, G. R., McNamara, J. P., Rahman, O.,… Murphy, T. K. (2013). Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive–compulsive disorder. Behaviour Research and Therapy, 51(12), 823829. doi:10.1016/j.brat.2013.09.007
Storch, E. A., McKay, D., Reid, J., Geller, D., Goodman, W., Lewin, A., & Murphy, T. (2010). D-Cycloserine augmentation of cognitive-behavioral therapy: Directions for pilot research in pediatric obsessive-compulsive disorder. Child and Youth Care Forum, 39(2), 101112. doi:10.1007/s10566-010–9094-6
Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J.,… Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 73(8), 779788. doi:10.1001/jamapsychiatry.2016.1128
Sulkowski, M. L., Geller, D. A., Lewin, A. B., Murphy, T. K., Mittelman, A., Brown, A., & Storch, E. A. (2014). The future of D-Cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. Current Psychiatry Reviews, 10(4), 317324. doi:10.2174/1573400510666140619224942
The Pediatric OCD Treatment Study (POTS) Team. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The pediatric OCD treatment study (POTS) randomized controlled trial. JAMA, 292(16), 19691976. doi:10.1001/jama.292.16.1969
Thomsen, P. H. (2004). Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: A case-series. Annals of Clinical Psychiatry, 16(4), 201207. doi:10.3109/10401230490522016
Varigonda, A. L., Jakubovski, E., & Bloch, M. H. (2016). Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 55(10), 851859. doi:10.1016/j.jaac.2016.07.768